Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis
Authors
Keywords
MOGAD, MOG, ADEM, Rituximab, Anti-CD20
Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 364, Issue -, Pages 577812
Publisher
Elsevier BV
Online
2022-01-14
DOI
10.1016/j.jneuroim.2022.577812
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis
- (2021) Yupeng Wang et al. Multiple Sclerosis and Related Disorders
- Myelin-oligodendrocyte glycoprotein antibody-associated disease
- (2021) Romain Marignier et al. LANCET NEUROLOGY
- Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders
- (2021) Elia Sechi et al. NEUROLOGY
- Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis
- (2021) Cong Zhao et al. Frontiers in Neurology
- MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
- (2020) Julia Loos et al. JOURNAL OF NEUROLOGY
- Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
- (2020) Yoshiki Takai et al. BRAIN
- Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
- (2020) Masayuki Tahara et al. LANCET NEUROLOGY
- Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis
- (2020) Gaurav Nepal et al. ACTA NEUROLOGICA SCANDINAVICA
- Treatment of MOG antibody associated disorders: results of an international survey
- (2020) D. H. Whittam et al. JOURNAL OF NEUROLOGY
- Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK
- (2020) Karen O'Connell et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder
- (2020) John J. Chen et al. NEUROLOGY
- Serious safety events in rituximab‐treated multiple sclerosis and related disorders
- (2020) Brandi L. Vollmer et al. Annals of Clinical and Translational Neurology
- Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey
- (2020) Berin Inan et al. Multiple Sclerosis and Related Disorders
- Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
- (2020) Daniel H Whittam et al. Multiple Sclerosis and Related Disorders
- Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
- (2019) Fulin Gao et al. BMC Neurology
- The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults
- (2019) CL de Mol et al. Multiple Sclerosis Journal
- Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
- (2019) Alvaro Cobo-Calvo et al. Journal of Neuroinflammation
- Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease
- (2019) Fahad Albassam et al. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
- Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases
- (2019) Pierre Durozard et al. ANNALS OF NEUROLOGY
- Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis
- (2018) Ilijas Jelcic et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders
- (2018) A. Sebastian López-Chiriboga et al. JAMA Neurology
- Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
- (2018) Yael Hacohen et al. JAMA Neurology
- MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
- (2018) Giordani Rodrigues dos Passos et al. Frontiers in Neurology
- Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
- (2018) Nadja Borisow et al. Frontiers in Neurology
- Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
- (2017) Sudarshini Ramanathan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders
- (2016) Valentina Damato et al. JAMA Neurology
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
- (2015) Dean M. Wingerchuk et al. NEUROLOGY
- The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
- (2012) De-Hyung Lee et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started